Skip to main navigation Skip to search Skip to main content

An International Standard for specifying the minimum potency of anti-D blood-grouping reagents: Evaluation of a candidate preparation in an international collaborative study

  • S. J. Thorpe*
  • , B. Fox
  • , A. B. Heath
  • , M. Scott
  • , M. de Haas
  • , S. Kochman
  • , A. Padilla
  • *Corresponding author for this work
  • Medicines and Healthcare Products Regulatory Agency
  • NHS Blood and Transplant
  • Sanquin Blood Supply Foundation
  • United States Food and Drug Administration
  • World Health Organization

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background and Objectives: The aim of this study was to evaluate a lyophilized monoclonal immunoglobulin M (IgM) anti-D preparation for use as an International Standard to specify a recommended minimum acceptable potency of anti-D blood-grouping reagents. Materials and Methods: The candidate International Standard (99/836) for specifying the minimum potency of anti-D blood-grouping reagents was evaluated against a wide range of commercial anti-D blood-grouping reagents in an international collaborative study involving 20 laboratories in 13 countries. Laboratories titrated reconstituted 99/836, in parallel with as many commercial anti-D blood-grouping reagents as were available to them, in tube tests according to specified haemagglutination methodology for low-protein (e.g. monoclonal IgM) and high-protein (e.g. polyclonal) reagents. The ratios of the mean end-point titres of the reagents to that of 99/836 within each laboratory were calculated. Results: The ratios of the mean titres of the low-protein reagents to the mean titre of 99/836 within a laboratory fell between 0.25 and 2 for 43 of the 45 low-protein anti-D reagents tested (i.e. the potencies of the low-protein reagents compared with 99/836 were between a 1:4 dilution of 99/836 to twice as potent as 99/836). The ratios of the mean titres of the high-protein reagents to the mean titre of 99/836 within a laboratory fell within 0.125 and 1 for eight out of the 10 high protein reagents tested. Conclusions: By international consensus, a 1:3 dilution of reconstituted 99/836 was deemed appropriate to define a recommended minimum acceptable potency of low-protein anti-D blood-grouping reagents. A 1:8 dilution of reconstituted 99/836 was deemed appropriate to define a recommended minimum acceptable potency of high-protein anti-D blood-grouping reagents. On the basis of the results presented here, 99/836 was established by the World Health Organization as the 1st International Standard for specifying the minimum potency of anti-D blood-grouping reagents, in tube tests. © 2005 Blackwell Publishing.
Original languageEnglish
Pages (from-to)131-139
JournalVox sanguinis
Volume90
Issue number2
DOIs
Publication statusPublished - Feb 2006
Externally publishedYes

Fingerprint

Dive into the research topics of 'An International Standard for specifying the minimum potency of anti-D blood-grouping reagents: Evaluation of a candidate preparation in an international collaborative study'. Together they form a unique fingerprint.

Cite this